As is our custom, we conclude the year by reflecting on the 10 most-read articles over the past 12 months. The list below reflects articles focused on investing, economics and financial planning.
Jeremy Grantham co-founded GMO in 1977 and serves as the firm’s chief investment strategist. Lucas White is the lead portfolio manager for the GMO Climate Change Strategy. In this interview, Jeremy and Lucas discus the risks and opportunities in climate-change-focused investing.
If sanctions against a target regime can be thought of as antibiotics, then North Korea has largely become drug-resistant. Indeed, North Korea is exhibiting “superbug” traits, increasingly impervious to sanctions, according to John Park.
Easy monetary policies during the post-crisis period have propelled equity prices higher and driven bond yields lower. But as central banks reverse their quantitative easing (QE) and raise rates, this “Goldilocks era” will come to an end, according to Jeffrey Gundlach.
The bull market in U.S. equities is behind us, according to Wharton professor Jeremy Siegel, who says that the S&P 500 is now “fairly priced.”
Those looking for an optimistic forecast for U.S. equities can turn to Northern Trust. Bob Browne, its chief investment officer, identified six themes that will drive the capital markets over the next five years. Taken together, they translate to 5.9% annual returns for U.S. stocks over that period, which includes 2017.
Neil Hennessy is a portfolio manager and chief investment officer at Hennessy Funds. In this interview, he discusses the compelling opportunities in mid-cap and Japanese stocks, and what RIAs should be doing in advance of the next market correction.
The money to be made is in non-U.S. markets, according to Jeffrey Gundlach. For long-term investors, he recommends a specific ETF.
Mohamed El-Erian says that investors have been “enticed to become increasingly exposed to historically illiquid asset class segments.” Here are the asset classes and ETFs that are most at risk.
The Wall Street Journal says that funds given a top “star” rating by Morningstar won’t be top performers. But the Journal’s findings are neither new nor as conclusive as its article states.
